Epidemiology and molecular evolution of norovirus GII.17 in the United States, 2021–2025

Clicks: 3
ID: 320001
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #264 of 427 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 427 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background GII.4 noroviruses have been the leading cause of acute gastroenteritis outbreaks in the United States (U.S.) for the past decade. Recently, GII.17 viruses have emerged globally, raising concerns about changes in disease burden and potential replacement of GII.4 as the predominant strain. Methods We characterized molecular and epidemiological features of U.S. GII.17 norovirus outbreaks from September 2021–August 2025 submitted to CaliciNet. Norovirus-positive outbreak samples were sequenced followed by RdRp and VP1 phylogenetic analyses. CaliciNet and National Outbreak Reporting System data were linked to compare GII.17 and GII.4 epidemiologic and clinical characteristics. Virus-like particles binding to gastric mucin and antibody blockade assays were conducted to assess antigenic variation among GII.17 variants. Results Among 1,412 outbreaks, GII.17 prevalence increased from 5.0% (2021–2022) to 74.8% (2024–2025). Compared with GII.4, GII.17 was more frequently reported with foodborne exposure (16.4% vs 9.6%), affected persons aged 10-49 years compared with other groups (31.1% vs 23.1%), and associated with slightly higher rates of vomiting (78.2% vs 72.2%), abdominal cramps (34.2% vs 30.1%), and fever (15.9% vs 10.9%). Phylogenetic analysis detected GII.17[P17] Romania-like (93.3%) followed by GII.17[P17] Kawasaki308-like strains (4.6%) and two novel tentative variants: Santa Clara (1.3%) and London (0.1%). Despite substitutions in key P2 antigenic sites, surrogate antibody neutralization remained conserved. Conclusion These findings indicate a recent shift in norovirus genotype dominance in the U.S., likely driven by enhanced transmissibility or population susceptibility rather than increased virulence. Continued molecular surveillance is essential to monitor viral evolution and public health impact of norovirus.
Reference Key
openalex_W7167727490 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Leslie Barclay, Mary E. Wikswo, H. G. Wall, Anita Kambhampati, Anna Montmayeur, Michael L. Mallory, Lisa C. Lindesmith, Sara A. Mirza, Ralph S. Baric, Jan Vinjé, Preeti Chhabra
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag348
URL
https://doi.org/10.1093/infdis/jiag348
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.